Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis.

Bernard CL, Owens DK, Goldhaber-Fiebert JD, Brandeau ML.

PLoS Med. 2017 May 24;14(5):e1002312. doi: 10.1371/journal.pmed.1002312. eCollection 2017 May.

2.

Effect of diet on type 2 diabetes mellitus: A review.

Sami W, Ansari T, Butt NS, Hamid MRA.

Int J Health Sci (Qassim). 2017 Apr-Jun;11(2):65-71. Review.

3.

Estimating State Transitions for Opioid Use Disorders.

Krebs E, Min JE, Evans E, Li L, Liu L, Huang D, Urada D, Kerr T, Hser YI, Nosyk B.

Med Decis Making. 2017 Jul;37(5):483-497. doi: 10.1177/0272989X16683928. Epub 2016 Dec 27.

PMID:
28027027
4.

Pressure RElieving Support SUrfaces: a Randomised Evaluation 2 (PRESSURE 2): study protocol for a randomised controlled trial.

Brown S, Smith IL, Brown JM, Hulme C, McGinnis E, Stubbs N, Nelson EA, Muir D, Rutherford C, Walker K, Henderson V, Wilson L, Gilberts R, Collier H, Fernandez C, Hartley S, Bhogal M, Coleman S, Nixon JE.

Trials. 2016 Dec 20;17(1):604.

5.

Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.

Dunlop WC, Mason N, Kenworthy J, Akehurst RL.

Pharmacoeconomics. 2017 Jan;35(1):125-128. doi: 10.1007/s40273-016-0479-8. No abstract available.

6.

Potential Impact of Biologically Derived Hyaluronic Acid on Quality of Life in Patients with Knee Osteoarthritis in the United States.

Rosen J, Sancheti P, Fierlinger A, Niazi F, Johal H, Bedi A.

Adv Ther. 2017 Jan;33(12):2200-2210. Epub 2016 Nov 3.

7.

Methods to construct a step-by-step beginner's guide to decision analytic cost-effectiveness modeling.

Rautenberg T, Hulme C, Edlin R.

Clinicoecon Outcomes Res. 2016 Oct 11;8:573-581. eCollection 2016.

8.

Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review.

Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M.

PLoS One. 2016 Sep 30;11(9):e0163880. doi: 10.1371/journal.pone.0163880. eCollection 2016.

9.

Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.

Yeung K, Basu A, Hansen RN, Watkins JB, Sullivan SD.

Med Care. 2017 Feb;55(2):191-198. doi: 10.1097/MLR.0000000000000630.

PMID:
27579915
10.

Multimorbidity in chronic disease: impact on health care resources and costs.

McPhail SM.

Risk Manag Healthc Policy. 2016 Jul 5;9:143-56. doi: 10.2147/RMHP.S97248. eCollection 2016. Review.

11.

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.

de Boer PT, Frederix GW, Feenstra TL, Vemer P.

Pharmacoeconomics. 2016 Sep;34(9):833-45. doi: 10.1007/s40273-016-0410-3. Review.

12.

Using physiologically based models for clinical translation: predictive modelling, data interpretation or something in-between?

Niederer SA, Smith NP.

J Physiol. 2016 Dec 1;594(23):6849-6863. doi: 10.1113/JP272003. Epub 2016 Jul 3. Review.

PMID:
27121495
13.

Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States.

Bernard CL, Brandeau ML, Humphreys K, Bendavid E, Holodniy M, Weyant C, Owens DK, Goldhaber-Fiebert JD.

Ann Intern Med. 2016 Apr 26. doi: 10.7326/M15-2634. [Epub ahead of print]

PMID:
27110953
14.

Activity-based cost analysis of hepatic tumor ablation using CT-guided high-dose rate brachytherapy or CT-guided radiofrequency ablation in hepatocellular carcinoma.

Schnapauff D, Collettini F, Steffen I, Wieners G, Hamm B, Gebauer B, Maurer MH.

Radiat Oncol. 2016 Feb 25;11:26. doi: 10.1186/s13014-016-0606-x.

15.

Economic evaluation of vaccines in Canada: A systematic review.

Chit A, Lee JK, Shim M, Nguyen VH, Grootendorst P, Wu J, Van Exan R, Langley JM.

Hum Vaccin Immunother. 2016 May 3;12(5):1257-64. doi: 10.1080/21645515.2015.1137405. Epub 2016 Feb 18.

16.

The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.

Catalá-López F, Ridao M, Alonso-Arroyo A, García-Altés A, Cameron C, González-Bermejo D, Aleixandre-Benavent R, Bernal-Delgado E, Peiró S, Tabarés-Seisdedos R, Hutton B.

Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5. Review.

17.

The Economic Impact of Lower Protein Infant Formula for the Children of Overweight and Obese Mothers.

Marsh K, Möller J, Basarir H, Orfanos P, Detzel P.

Nutrients. 2016 Jan 2;8(1). pii: E18. doi: 10.3390/nu8010018.

18.

How to Measure Costs and Benefits of eHealth Interventions: An Overview of Methods and Frameworks.

Bergmo TS.

J Med Internet Res. 2015 Nov 9;17(11):e254. doi: 10.2196/jmir.4521. Review.

19.

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, Knol M, von Kries R, Kuhlmann A, Levy-Bruhl D, Perleth M, Postma M, Salo H, Siebert U, Wasem J, Wichmann O.

Pharmacoeconomics. 2016 Mar;34(3):227-44. doi: 10.1007/s40273-015-0335-2.

Supplemental Content

Support Center